Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (281-290 of 319) with videos related to

Pageof 32
Sort By:
The Journal of Urology|March 23, 2023
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate CancerAdam C Schneider, Thenappan Chandrasekar, Nicholas Bowler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
JCO Precision Oncology|February 14, 2024
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate CancerPhilip J Saylor, Keisuke Otani, Rene Balza, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Associations between Exposure to Perfluoroalkyl Substances with Subsequent Body Composition and Glycemic Responses to Bariatric SurgerySaketh Sankara, Matthew R Smith, Stephanie M Eick, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
Cancer Discovery|October 25, 2012
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancerDavid T Miyamoto, Richard J Lee, Shannon L Stott, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Cancer Medicine|November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysisMotohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
Pageof 32

Showing results (281-290 of 319) with videos related to

Sort By:
Pageof 32
The Journal of Urology|March 23, 2023
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate CancerAdam C Schneider, Thenappan Chandrasekar, Nicholas Bowler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
JCO Precision Oncology|February 14, 2024
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate CancerPhilip J Saylor, Keisuke Otani, Rene Balza, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Associations between Exposure to Perfluoroalkyl Substances with Subsequent Body Composition and Glycemic Responses to Bariatric SurgerySaketh Sankara, Matthew R Smith, Stephanie M Eick, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
Cancer Discovery|October 25, 2012
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancerDavid T Miyamoto, Richard J Lee, Shannon L Stott, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Cancer Medicine|November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysisMotohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
Pageof 32